Servier Fragile X acquisition involves KER-0193, enhancing its neurology pipeline with a $450m deal.
• Servier acquires KER-0193 for $450m on October 2023.
• Deal covers Fragile X syndrome treatment, global rights.
• Enhances Servier’s neurology pipeline, targets rare diseases.
Servier has acquired KER-0193, a potential treatment for Fragile X syndrome, from Kaerus Bioscience. The deal could be worth up to $450 million if all development and commercial milestones are met. This acquisition marks Servier’s first asset in neurology, aligning with its strategy to build a leading franchise in rare diseases. Read more about the acquisition.
Why it matters
Fragile X syndrome is the most common genetic cause of autism spectrum disorder, affecting approximately 1 in 7,000 males and 1 in 11,000 females globally. Currently, there are no approved treatments for this condition. Therefore, KER-0193 offers a promising new option for patients with unmet needs. The drug has already cleared a phase I clinical trial and holds Orphan Drug and Rare Pediatric Drug designations from the US Food and Drug Administration (FDA).
What’s next
The acquisition will enable Servier to advance KER-0193 into phase II trials in the US and Europe next year. This move is part of Servier’s broader strategy to establish a differentiated pipeline of innovative therapies. The company aims to address underserved needs in neurology, particularly focusing on rare diseases. For further insights into Servier’s strategic initiatives, visit our insights section.